sophia genetics sa - SOPH
SOPH
Close Chg Chg %
8.09 0.27 3.34%
Pre-Market
8.36
+0.27 (3.34%)
Volume: 461.98K
Last Updated:
Sep 8, 2026, 4:00 PM EDT
Company Overview: sophia genetics sa - SOPH
SOPH Key Data
| Open $7.99 | Day Range 7.86 - 8.39 |
| 52 Week Range 3.10 - 8.98 | Market Cap $678.71M |
| Shares Outstanding 83.90M | Public Float 60.42M |
| Beta 0.98 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.15 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 523.14K |
SOPH Performance
| 1 Week | 0.00% | ||
| 1 Month | 4.93% | ||
| 3 Months | 65.78% | ||
| 1 Year | 159.29% | ||
| 5 Years | -52.38% |
SOPH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About sophia genetics sa - SOPH
SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.
SOPH At a Glance
SOPHiA GENETICS SA
La Piece 12
Rolle, Vaud 1025
| Phone | 41-21-694-10-60 | Revenue | 77.27M | |
| Industry | Packaged Software | Net Income | -78,999,000.00 | |
| Sector | Technology Services | 2025 Sales Growth | 18.563% | |
| Fiscal Year-end | 12 / 2026 | Employees | 415 | |
| View SEC Filings |
SOPH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.082 |
| Price to Book Ratio | 6.784 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.019 |
| Enterprise Value to Sales | 3.988 |
| Total Debt to Enterprise Value | 0.205 |
SOPH Efficiency
| Revenue/Employee | 186,195.181 |
| Income Per Employee | -190,359.036 |
| Receivables Turnover | 4.171 |
| Total Asset Turnover | 0.483 |
SOPH Liquidity
| Current Ratio | 1.961 |
| Quick Ratio | 1.835 |
| Cash Ratio | 1.391 |
SOPH Profitability
| Gross Margin | 61.878 |
| Operating Margin | -91.787 |
| Pretax Margin | -101.574 |
| Net Margin | -102.236 |
| Return on Assets | -49.395 |
| Return on Equity | -110.00 |
| Return on Total Capital | -71.71 |
| Return on Invested Capital | -68.163 |
SOPH Capital Structure
| Total Debt to Total Equity | 133.673 |
| Total Debt to Total Capital | 57.205 |
| Total Debt to Total Assets | 38.555 |
| Long-Term Debt to Equity | 127.946 |
| Long-Term Debt to Total Capital | 54.754 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Sophia Genetics Sa - SOPH
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 47.56M | 62.37M | 65.17M | 77.27M | |
Sales Growth
| +17.58% | +31.14% | +4.49% | +18.56% | |
Cost of Goods Sold (COGS) incl D&A
| 20.74M | 25.70M | 26.31M | 29.46M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 5.57M | 8.34M | 8.60M | 9.53M | |
Depreciation
| 3.79M | 5.51M | 4.58M | 3.98M | |
Amortization of Intangibles
| 1.78M | 2.83M | 4.02M | 5.55M | |
COGS Growth
| +13.02% | +23.87% | +2.39% | +11.97% | |
Gross Income
| 26.82M | 36.68M | 38.87M | 47.81M | |
Gross Income Growth
| +21.37% | +36.77% | +5.97% | +23.03% | |
Gross Profit Margin
| +56.38% | +58.80% | +59.63% | +61.88% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 116.31M | 113.59M | 106.34M | 118.74M | |
Research & Development
| 34.92M | 35.60M | 33.13M | 33.57M | |
Other SG&A
| 81.39M | 77.98M | 73.21M | 85.17M | |
SGA Growth
| +22.06% | -2.34% | -6.38% | +11.66% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 73.00K | (370.00K) | 3.82M | |
EBIT after Unusual Expense
| (89.57M) | (76.91M) | (67.11M) | (74.75M) | |
Non Operating Income/Expense
| 1.33M | (2.13M) | 7.02M | 814.00K | |
Non-Operating Interest Income
| 1.32M | 4.55M | 3.36M | 1.87M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 639.00K | 588.00K | 1.91M | 4.55M | |
Interest Expense Growth
| -2.89% | -7.98% | +225.34% | +138.06% | |
Gross Interest Expense
| 639.00K | 588.00K | 1.91M | 4.55M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (88.88M) | (79.62M) | (62.00M) | (78.49M) | |
Pretax Income Growth
| -18.34% | +10.41% | +22.14% | -26.60% | |
Pretax Margin
| -186.87% | -127.66% | -95.13% | -101.57% | |
Income Tax
| (1.43M) | (643.00K) | 497.00K | 512.00K | |
Income Tax - Current - Domestic
| (18.00K) | 255.00K | 1.27M | 1.54M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (118.00K) | 231.00K | (47.00K) | (30.00K) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| 1.29M | 1.13M | 726.00K | 1.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (87.45M) | (78.98M) | (62.49M) | (79.00M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (87.45M) | (78.98M) | (62.49M) | (79.00M) | |
Net Income Growth
| -18.70% | +9.68% | +20.88% | -26.41% | |
Net Margin Growth
| -183.87% | -126.63% | -95.89% | -102.24% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (87.45M) | (78.98M) | (62.49M) | (79.00M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (87.45M) | (78.98M) | (62.49M) | (79.00M) | |
EPS (Basic)
| -1.3643 | -1.2198 | -0.946 | -1.1697 | |
EPS (Basic) Growth
| -18.25% | +10.59% | +22.45% | -23.65% | |
Basic Shares Outstanding
| 64.10M | 64.75M | 66.06M | 67.54M | |
EPS (Diluted)
| -1.3643 | -1.2198 | -0.946 | -1.1697 | |
EPS (Diluted) Growth
| -18.25% | +10.59% | +22.45% | -23.65% | |
Diluted Shares Outstanding
| 64.10M | 64.75M | 66.06M | 67.54M | |
EBITDA
| (83.92M) | (68.57M) | (58.88M) | (61.40M) | |
EBITDA Growth
| -20.60% | +18.29% | +14.13% | -4.27% | |
EBITDA Margin
| -176.45% | -109.94% | -90.35% | -79.46% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 9.00 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.198 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -0.938 | |
| Last Quarter’s Earnings | -0.30 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.17 | Next Fiscal Year Estimate | -0.626 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 5 | 5 |
| Mean Estimate | -0.20 | -0.17 | -0.94 | -0.63 |
| High Estimates | -0.13 | -0.06 | -0.77 | -0.31 |
| Low Estimate | -0.24 | -0.20 | -1.01 | -0.77 |
| Coefficient of Variance | -20.64 | -36.26 | -10.18 | -28.99 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Sophia Genetics Sa - SOPH
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Sophia Genetics Sa - SOPH
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 27, 2026 | Kathy L. Hibbs Director | 103,242 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.68 per share | 896,140.56 |
| Aug 27, 2026 | Abhimanyu Verma Chief Technology Officer | 172,171 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.8 per share | 1,515,104.80 |
| Aug 27, 2026 | Abhimanyu Verma Chief Technology Officer | 177,171 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.2 per share | 1,452,802.20 |
| Aug 27, 2026 | Philippe Menu Chief Medical Officer | 213,387 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.68 per share | 1,852,199.16 |
| Jun 24, 2026 | George A. Cardoza Chief Financial Officer | 310,684 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.38 per share | 1,671,479.92 |
| Jun 24, 2026 | Ross Muken President | 680,489 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.38 per share | 3,661,030.82 |
| Apr 22, 2026 | Zhenyu Xu Chief Scientific Officer | 630,888 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.21 per share | 3,286,926.48 |
| Apr 22, 2026 | Kevin Puylaert Chief Sales Officer | 148,197 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.08 per share | 752,840.76 |
| Apr 22, 2026 | Manuela da Silva Valente Chief People Officer | 215,071 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.2 per share | 1,118,369.20 |
| Apr 22, 2026 | Jurgi Camblong Chief Executive Officer; Director | 3,642,481 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.2 per share | 18,940,901.20 |
| Apr 22, 2026 | Daan G. M. van Well Chief Legal Officer | 345,736 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.2 per share | 1,797,827.20 |
| Apr 17, 2026 | Jurgi Camblong Chief Executive Officer; Director | 3,646,967 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5 per share | 18,234,835.00 |
| Apr 15, 2026 | Jurgi Camblong Chief Executive Officer; Director | 3,707,569 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.76 per share | 17,648,028.44 |
| Apr 15, 2026 | Zhenyu Xu Chief Scientific Officer | 635,496 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.76 per share | 3,024,960.96 |
| Apr 15, 2026 | Zhenyu Xu Chief Scientific Officer | 632,096 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.76 per share | 3,008,776.96 |
| Apr 15, 2026 | Philippe Menu Chief Medical Officer | 271,996 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.76 per share | 1,294,700.96 |
| Apr 15, 2026 | Philippe Menu Chief Medical Officer | 268,596 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.76 per share | 1,278,516.96 |
| Apr 15, 2026 | Ross Muken President | 685,232 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.76 per share | 3,261,704.32 |
| Apr 9, 2026 | Daan G. M. van Well Chief Legal Officer | 142,216 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2026 | Kevin Puylaert Chief Sales Officer | 148,230 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.83 per share | 715,950.90 |